CALC
CalciMedica·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CALC
Calcimedica, Inc.
A clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs
505 Coast Boulevard South, Suite 307, La Jolla, California 92037
--
CalciMedica, Inc., was incorporated in February 2015 under the laws of the State of Delaware. The company is a clinical-stage biopharmaceutical company focused on developing therapies for serious diseases driven by inflammation and immune processes as well as direct cell damage. The Company's product candidate acts on the calcium release activated calcium (" CRAC ") channel and will constitute a class of new drugs.
Company Financials
EPS
CALC has released its 2025 Q3 earnings. EPS was reported at -0.52, versus the expected -0.41, missing expectations. The chart below visualizes how CALC has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
